Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Tuesday, January 14, 2025, at 11:15 a.m. Pacific Time.

Interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. An archived version of the presentation will also be made available on the company's website following the live broadcast.

News Market Reaction

-3.73%

1 alert

-3.73% News Effect

On the day this news was published, AKRO declined 3.73%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. P.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero’s lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated with EFX or placebo for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
Christina.tartaglia@precisionaq.com

Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com 

FAQ

When is Akero Therapeutics (AKRO) presenting at the J.P. Morgan Healthcare Conference 2025?

Akero Therapeutics will present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. Pacific Time.

How can investors watch Akero Therapeutics' J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on Akero's investor relations website at www.akerotx.com. An archived replay will also be available after the event.

What is the focus of Akero Therapeutics' (AKRO) drug development program?

Akero Therapeutics focuses on developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.

Which annual J.P. Morgan Healthcare Conference is AKRO presenting at?

Akero Therapeutics is presenting at the 43rd Annual J.P. Morgan Healthcare Conference.